ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: SA-PO199

The Clinico-Pathologic Characteristics of Patients with Proliferative Glomerulonephritis with Monoclonal Immunoglobulin Deposits

Session Information

Category: Onconephrology

  • 1700 Onconephrology


  • Gudura, Tariku T., Cleveland Clinic, Cleveland, Ohio, United States
  • Sawaf, Hanny, Cleveland Clinic, Cleveland, Ohio, United States
  • Herlitz, Leal C., Cleveland Clinic, Cleveland, Ohio, United States
  • Mehdi, Ali, Cleveland Clinic, Cleveland, Ohio, United States
  • Gebreselassie, Surafel K., Cleveland Clinic Florida, Weston, Florida, United States
  • Bobart, Shane A., Cleveland Clinic Florida, Weston, Florida, United States

Proliferative glomerulonephritis with monoclonal immunoglobin (Ig) deposits (PGNMID) is a rare form of monoclonal gammopathy of renal significance (MGRS). However, the Monoclonal (M) protein and hematologic clone is found in less than half of the cases.


We identified all patients with PGNMID from the Cleveland Clinic Kidney Biopsy Epidemiology Project from January 2015 to March 2023. Retrospective chart review was performed to obtain demographic and clinical characteristics.


From 34 patients with PGNMID, 16 patients were excluded due to insufficient data. Of the 18 remaining patients, 67% were male and 78% of patients self-reported as white. The median age was 60 years, with 22% of patients < 50 years. Clinically, features at kidney biopsy were: hypertension (78%), acute kidney injury (72%), hematuria (78%), nephrotic syndrome (22%), and hypocomplementemia (23%). M protein was identified in 33% with an underlying clone identified in only 17% (3/18) of cases (MM, CLL and B cell lymphoma). Mean serum creatinine and proteinuria at biopsy were 3.2mg/dl (0.64 - 9.0) and 4.3 gm/dl (0 - 14.0gm) respectively.
Regarding pathology, endocapillary hypercellularity (55%), pure mesangial (28%) and MPGN (16%) patterns were most common. The majority of patients (>65%) had mild chronicity and 1 case had crescents. IgG/Kappa was the predominant finding (83%), one patient had IgM/Kappa. Of 13 patients with IgG subclass staining, 77% had IgG3 and one case each of IgG1, IgG2 and IgG4. CyBorD and CyBord-Daratumumab were the most common chemotherapy regimens used, each accounting 35% followed by Rituximab in 12% of cases.
Regarding outcomes, 18 patients had follow up data, with 8 (44%) progressing to ESKD post biopsy with mean duration of 7.8 months (0 - 13) and 44% had either complete (< 0.5 g) or partial remission (proteinuria reduction > 50% with stable eGFR) during follow up. No clinico-pathologic variables were predictive of response on univariate and multivariable analysis.


Our study adds to growing evidence of low clonal detection rate among patients with PGNMID and high rate of disease progression despite treatment. More studies are needed to better understand the true nature of this disease to hopefully guide therapeutic interventions.